Caris Life Sciences, Inc. (NASDAQ:CAI – Get Free Report) insider John Russel Denton sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $31.82, for a total transaction of $238,650.00. Following the completion of the transaction, the insider directly owned 174,855 shares in the company, valued at approximately $5,563,886.10. The trade was a 4.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Caris Life Sciences Stock Down 0.9%
Shares of NASDAQ CAI opened at $31.98 on Friday. The company has a current ratio of 5.53, a quick ratio of 4.88 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average of $23.19 and a 200-day moving average of $19.76. The firm has a market capitalization of $9.04 billion, a price-to-earnings ratio of 88.83 and a beta of 1.10. Caris Life Sciences, Inc. has a 12 month low of $14.19 and a 12 month high of $33.65.
Caris Life Sciences declared that its Board of Directors has approved a share repurchase plan on Monday, June 8th that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 2.1% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.
Hedge Funds Weigh In On Caris Life Sciences
Analysts Set New Price Targets
Several research firms have recently commented on CAI. UBS Group initiated coverage on Caris Life Sciences in a report on Wednesday, September 9th. They issued a “neutral” rating and a $28.00 price objective on the stock. BTIG Research increased their target price on Caris Life Sciences from $32.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wall Street Zen upgraded Caris Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Evercore reaffirmed an “outperform” rating and issued a $26.00 price target on shares of Caris Life Sciences in a research note on Thursday, August 6th. Finally, Weiss Ratings upgraded Caris Life Sciences from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, September 16th. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Caris Life Sciences has a consensus rating of “Hold” and a consensus price target of $26.50.
Check Out Our Latest Research Report on CAI
Caris Life Sciences Company Profile
Caris Life Sciences is a precision medicine and biotechnology company headquartered in Irving, Texas. Founded in 2008, the company combines molecular profiling, artificial intelligence and clinical data to support more informed decisions in cancer diagnosis and treatment.
Caris provides comprehensive tumor profiling and other laboratory testing services designed to identify genetic, molecular and immune characteristics of a patient’s cancer. Its offerings are intended to help physicians match patients with targeted therapies, immunotherapies and clinical trials, while also supporting cancer research and drug development.
The company serves healthcare providers, biopharmaceutical companies and academic or research institutions.
Further Reading
- Five stocks we like better than Caris Life Sciences
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Caris Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caris Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
